By acquiring RayzeBio, Bristol Myers Squibb gains a pipeline of radiopharmaceuticals and the infrastructure for manufacturing these targeted cancer therapies. In the second half of 2023 alone, BMS has committed about $24 billion to business development deals.
RayzeBio Nets $160M in Series D - San Diego Business Journal sdbj.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from sdbj.com Daily Mail and Mail on Sunday newspapers.
RayzeBio Snags $108M for Cancer Drug Efforts socaltech.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from socaltech.com Daily Mail and Mail on Sunday newspapers.